Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290147 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00290147: Completed Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT00290147 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00290147, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
Primary Outcome
Summary of ungraded systemic and local reactogenicity symptoms following each vaccination
Interventions
- BIOLOGICAL D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00290147 record still lists
NCT00290147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which D1ME100 (dengue-1 premembrane/envelope DNA vaccine) is the first listed.
NCT00290147 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00290147 about?
NCT00290147 is a clinical study titled "Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine". The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
What is the current status of trial NCT00290147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00290147?
The interventions under investigation include: D1ME100 (dengue-1 premembrane/envelope DNA vaccine) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00290147?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00290147's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia